Speaker Profile
Ph.D., CEO, Numiera Tx
Biography
Izi Stoll is CEO of Numiera Therapeutics and Scientific Director of the Western Institute for Advanced Study. She received bachelors degrees in Biology and Psychology from the University of Illinois at Urbana-Champaign, then earned her doctorate in Neurobiology and Behavior from the University of Washington. Dr. Stoll completed her postdoctoral research at the Wellcome Trust Centre for Mitochondrial Research, then started her own laboratory at Newcastle University, leading parallel research teams to develop new targeted therapies for cancer and lentiviral-based gene therapies for epilepsy. She has won awards for her work from the Society for Neuro Oncology and The American Federation for Aging Research. Now, as Scientific Director of the Western Institute for Advanced Study, she leads interdisciplinary teams to tackle the organizations Grand Challenges. And as CEO of Numiera Therapeutics, she is leading on the clinical development of a first-in-class target in cancer cell metabolism.
Talk
CPT1 as a novel target in oncology
With Phase I clinical data indicating improved safety over standard-of-care, and independently-replicated preclinical efficacy data from five laboratories, Numiera Therapeutics is repurposing its first-in-class CPT1 inhibitor for the treatment of glioblastoma. With orphan drug designation already in place, the company is raising a $10M equity financing round to support clinical trials and additional pipeline development.
Wellness & Aging Showcase:
Numiera Therapeutics
Numiera Therapeutics is developing small-molecule drugs for oncology indications, with a novel target in cancer cell metabolism.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Large Scale Data Solutions Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
